CHR(CHR)
CHR
No analyst ratings available
No analyst price targets available for CHR
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $163M | $176M | $207M |
| Low | $163M | $176M | $207M |
| High | $163M | $176M | $207M |
| EBITDA Avg | $35M | $38M | $45M |
| Low | $35M | $38M | $45M |
| High | $35M | $38M | $45M |
| EBIT Avg | $31M | $34M | $39M |
| Low | $31M | $34M | $39M |
| High | $31M | $34M | $39M |
| Net Income Avg | $798M | $766M | $1.21B |
| Low | $798M | $766M | $1.21B |
| High | $798M | $766M | $1.21B |
| EPS Avg | $750.00 | $720.00 | $1140.00 |
| Low | $750.00 | $720.00 | $1140.00 |
| High | $750.00 | $720.00 | $1140.00 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 |
|---|---|---|---|
| Revenue Avg | $103M | $87M | $120M |
| Low | $103M | $87M | $120M |
| High | $103M | $87M | $120M |
| EBITDA Avg | $22M | $19M | $26M |
| Low | $22M | $19M | $26M |
| High | $22M | $19M | $26M |
| EBIT Avg | $20M | $17M | $23M |
| Low | $20M | $17M | $23M |
| High | $20M | $17M | $23M |
| Net Income Avg | $78M | $124M | $106M |
| Low | $78M | $124M | $106M |
| High | $78M | $124M | $106M |
| EPS Avg | $390.00 | $615.00 | $525.00 |
| Low | $390.00 | $615.00 | $525.00 |
| High | $390.00 | $615.00 | $525.00 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 |